期刊
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
卷 14, 期 5, 页码 857-872出版社
SPRINGER
DOI: 10.1007/s12265-021-10108-w
关键词
Epitranscriptomics; N6-methyladenosine (m(6)A); Methyltransferase; Demethylase; Cardiovascular diseases
资金
- Key Project of Hunan Provincial Department of Education [20A427]
- National Natural Sciences Foundation of China [81970390, 82060065]
- Natural Science Foundation of Hunan Province [2018JJ3455, 2018JJ2341, 2019JJ40249]
- Key Project of the Natural Science Foundation of Guangxi Zhuang Autonomous Region, China [2020GXNSFDA297011]
- Foundation for Guangxi Key Laboratory of Diabetic Systems Medicine [20-065-77]
- Outstanding Young Aid Program for Education Department of Hunan Province [18B274]
- Major Project of social science achievement review committee in Hunan Province [XSP20ZDI013]
- Hunan Provincial Innovation Foundation For Postgraduate [CX20200965]
N6-methyladenosine (m(6)A) is the most abundant and prevalent epigenetic modification of mRNA in mammals, regulating the fate of target mRNAs by influencing splicing, translation, and decay. Its important role in cardiovascular diseases, such as cardiac remodeling, heart failure, atherosclerosis, and congenital heart disease, has been highlighted in recent studies, although the exact mechanisms are not fully elucidated.
N6-methyladenosine (m(6)A) is the most abundant and prevalent epigenetic modification of mRNA in mammals. This dynamic modification is regulated by m(6)A methyltransferases and demethylases, which control the fate of target mRNAs through influencing splicing, translation and decay. Recent studies suggest that m(6)A modification plays an important role in the progress of cardiac remodeling and cardiomyocyte contractile function. However, the exact roles of m(6)A in cardiovascular diseases (CVDs) have not been fully explained. In this review, we summarize the current roles of the m(6)A methylation in the progress of CVDs, such as cardiac remodeling, heart failure, atherosclerosis (AS), and congenital heart disease. Furthermore, we seek to explore the potential risk mechanisms of m(6)A in CVDs, including obesity, inflammation, adipogenesis, insulin resistance (IR), hypertension, and type 2 diabetes mellitus (T2DM), which may provide novel therapeutic targets for the treatment of CVDs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据